dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Stilgenbauer, Stephan |
dc.contributor.author | Bosch Albareda, Francesc |
dc.contributor.author | Ilhan, Osman |
dc.contributor.author | Kisro, Jens |
dc.contributor.author | Mahé, Béatrice |
dc.contributor.author | Mikuskova, Eva |
dc.date.accessioned | 2021-06-23T11:14:36Z |
dc.date.available | 2021-06-23T11:14:36Z |
dc.date.issued | 2021-04 |
dc.identifier.citation | Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahé B, Mikuskova E, et al. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Br J Haematol. 2021 Apr;193(2):325-338. |
dc.identifier.issn | 1365-2141 |
dc.identifier.uri | https://hdl.handle.net/11351/6091 |
dc.description | Obinutuzumab; Leucemia linfocítica crónica; Enfermedad residual mínima |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | British Journal of Haematology;193(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia limfocítica crònica |
dc.subject | Quimioteràpia combinada |
dc.subject | Prognosi |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Treatment Outcome |
dc.title | Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/bjh.17326 |
dc.subject.decs | leucemia linfocítica crónica de células B |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://onlinelibrary.wiley.com/doi/10.1111/bjh.17326 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Stilgenbauer S] Department of Internal Medicine III, Ulm University, Ulm and Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany. [Bosch F] Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ilhan O] Internal Medical Sciences Departments, Ankara University School of Medicine, Ankara, Turkey. [Kisro J] Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany. [Mahé B] Clinical Hematology, CHU Nantes Hôtel-Dieu, Nantes, France. [Mikuskova E] Department of Hemato-oncology II, National Cancer Institute, Bratislava, Slovakia Blokhin |
dc.identifier.pmid | 33605445 |
dc.identifier.wos | 000619541700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |